Intellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.
Chad Watson
Advertisement
Articles by Chad Watson
Advertisement
Latest Updated Articles
- Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck Decision
Published: May 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5
